Knowing which infections in a population are recent and the ability to estimate incidence is of value to epidemiologists, public health officials, HIV intervention program managers and vaccine trial coordinators because it identifies the “hot spots” of infections. When those spots are determined, targeted populations are identified and decisions can be made about where to focus intervention efforts to maximize use of public health resources. This information is also useful to determine if HIV intervention efforts are working by monitoring whether the proportion of recent HIV infections is declining. The first generation of laboratory incidence tests offered the same approach, but were made by modifying commercial HIV diagnostic products to make them less sensitive, based on the principle of higher antibody levels in long term infections. Unfortunately, such an approach had a variable response to different HIV serotypes, since nearly all commercial diagnostic tests are made with only B serotype antigens, while the LAg-Avidity EIA was designed to react across all HIV serotypes. Sedia has quickly become the primary supplier of these assays, the fundamental technology of which was developed by the U.S. Centers for Disease Control and Prevention (CDC). In fact, all of Sedia’s HIV-1 Incidence Assays are tested and qualified by the CDC prior to product release. The assays are used as tools for monitoring the spread of HIV infections around the world, and are broadly preferred by experts in the area of HIV surveillance over other laboratory assay technologies.